The New Era of Neuromyelitis Optica Spectrum Disorder: Advances in Diagnosis and Treatment
Please read the CME/CE information below, then click the "Begin Activity" button to continue.
Date of Release: February 12, 2021
Expires on: February 12, 2022
Time to Complete: 1.0 hour
This CME/CE activity is jointly provided by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.
Commercial Support Acknowledgment
This activity is supported by independent educational grants from Alexion Pharmaceuticals and Genentech.
This activity is a recording of live events that occurred on 1/14/2021 and on 1/19/2021.
This activity is intended for neurologists, nurses, nurse practitioners, PAs, pharmacists, and other members of the healthcare team essential to the diagnosis and management of patients with neuromyelitis optica spectrum disorder.
- Define symptoms of NMOSD and common diseases that mimic NMOSD
- Summarize consensus diagnostic criteria for NMOSD
- Review diagnostic testing methods for NMOSD
- Employ team-based approaches to the early and accurate diagnosis of NMOSD
- Review novel treatment options for NMOSD
- Apply evidence-based approaches to personalizing treatment for patients with NMOSD
Brian G. Weinshenker, MD, FRCP(C)
Consultant, Department of Neurology
Professor of Neurology, College of Medicine
Marcelo Matiello, MD
Assistant Professor of Neurology, Harvard Medical School
Director, Massachusetts General Hospital Neurology Inpatient Services
Director, Massachusetts General Hospital Routine and Urgent Teleneurology Program
Associate Director, Neuromyelitis Optica Clinic and Research Unit
Accreditation Statement and Credit Designations
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The CMSC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit Designation
The CMSC designates this activity for a maximum of 1.0 contact hours of continuing nursing education (0.5 in the area of pharmacology).
This knowledge-based activity, UAN JA4008165-9999-21-002-H01-P, qualifies for 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit.
Disclosures of Conflicts of Interest
It is the policy of the Consortium of Multiple Sclerosis Centers (CMSC) to ensure balance, independence, objectivity, and scientific rigor in all educational activities. All faculty, planning committee members, content reviewers, and staff participating in this activity have disclosed any relevant financial relationships they or their significant other have had within the previous 12 months with manufacturers of any commercial products/devices and/or providers of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. All presentations were reviewed by an independent clinician with no relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.
The following faculty report that they have relevant financial relationships to disclose:
Brian G. Weinshenker, MD, FRCP(C)
Dr. Weinshenker has disclosed the following relationships:
Royalty: Hospices Civils de Lyon, MVZ Labor PD Dr. Volkmann und Kollegen GbR, Oxford University, RSR Limited
Receipt of Intellectual Property Rights/Patent Holder: Patent for use of NMO-IgG as diagnostic test for neuromyelitis optica spectrum disorder
Consulting Fee: Chugai/Roche/Genentech (satralizumab clinical trial); Mitsubishi Tanabe (trial design)
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Its Agent: Genentech
Other: Chair for attack adjudication committee for Alexion and MedImmune/Viela Bio
Marcelo Matiello, MD
Dr. Matiello has disclosed the following relationships:
Consulting Fee: Viela Bio
Activity Staff Disclosures
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP served as planners and reviewers and have declared that they have no relevant financial relationships to disclose.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.
Method of Participation
There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive credit, participants must read the CME/CE information and faculty disclosures, complete the pre-test questions, view the activity, and complete the post-test and evaluation form. Statements of Credit are awarded upon successful completion of the post-test, with a passing score of 65%, and evaluation form.
Certificates will be emailed to the participant.
For information about this program, please contact Catamount Medical Education at: email@example.com.
Disclosure of Unlabeled Use
CMSC and Catamount Medical Education require CME/CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
During this presentation, Dr. Weinshenker may reference rituximab, tocilizumab, and other immunosuppressant medications to treat neuromyelitis optica spectrum disorder. Dr. Matiello may reference azathioprine, prednisone, mycophenolate mofetil, methotrexate, mitoxantrone, and plasmapheresis.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For CME/CE questions, please contact Catamount Medical Education at: firstname.lastname@example.org.